Nepafenac CAS NO.78281-72-8

Min.Order Quantity:: 100 Metric Ton

Purity:: 98%min

Port:: Qingdao,China

Payment Terms:: L/C,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

78281-72-8
Sell high quality Nepafenac produced in China factory
78281-72-8 seller in China

Quick Details

ProName: Nepafenac
CasNo: 78281-72-8
Molecular Formula: C15H14N2O2
Appearance: powder
Application: Used for research and industrial manuf...
DeliveryTime: Within7-10 days after receipt of your ...
PackAge: As customer request
Port: Qingdao,China
ProductionCapacity: 100kg/Month Metric Ton/Day
Purity: 98%min
Storage: Store in a cool,dry place and keep awa...
Transportation: Common products:Sea/Air/Courier Dange...
LimitNum: 100 Metric Ton

Superiority

Details

product name:	nepafenac
synonyms:	nepafenac;2-(2-amino-3-benzoyl-phenyl)acetamide;2-amino-3-benzoylbenzeneacetamide;nepafenac,nevance;nepafanac;ahr 9434;al 6515;nevanac
cas:	78281-72-8
mf:	c15h14n2o2
mw:	254.28
einecs:
product categories:	amines;aromatics;intermediates & fine chemicals;isotope labelled compounds;pharmaceuticals;pharmaceutical intermediate;nevanac;other apis
mol file:	78281-72-8.mol

nepafenac chemical properties

mp	177-181°c
storage temp.	refrigerator
cas database reference	78281-72-8(cas database reference)

safety information

hazard codes	n
risk statements	50/53
safety statements	60-61

msds information

nepafenac usage and synthesis

ophthalmic drugs (cataract)	nepafenac is a novel ophthalmic non-steroidal anti-inflammatory drug (nsaid), for the treatment of eye pain and inflammation caused by cataract surgery, compared with traditional nsaids, chemical structure of nepafenac is conducive to make it rapidly penetrate the cornea and distribute to its target site, which is helpful to reduce the accumulation of the drug in the corneal surface and to reduce the incidence of complications of the eye surface, it has many advantages such as infiltration, targeting strong, little toxic side effects and so on. august 19, 2005 ,the us food and drug administration (fda) approved nepafenac ophthalmic suspension for the treatment of cataract surgery-related pain and inflammation, it is the first ophthalmic nsaid prodrug formulation approved for marketing. nepafenac after ocular administration, can rapidly pass through the cornea , and under the action of eye tissue hydrolytic enzymes,it can become into ammonia diclofenac (a kind of nsaid); and ammonia diclofenac by inhibiting prostaglandin h synthase ( cyclooxygenase), can block prostaglandin synthesis to play its role as an anti-inflammatory analgesic. as is known, prostaglandin is one of the media causing ocular inflammation it can lead to blood - aqueous barrier crash, vasodilatation, increased vascular permeability and leukocyte chemotaxis, etc. in addition, prostaglandins can also control contraction of the iris sphincter through non-cholinergic mechanism which can trigger the miosis reaction during eye surgery and after surgery. after ocular administration of nsaids, it can inhibit prostaglandins synthesis in the iris, ciliary body and conjunctiva, so people can prevent eye inflammation, and reduce the associated pain. the above information is edited by the chemicalbook of tian ye.
chemical properties	light yellow solid
usage	nepafenac is a non-steroidal anti-inflammatory drug (nsaid), usually sold as a prescription eye drop. it reduces pain and inflammation in the eyes. nepafenac ophthalmic is used to reduce pain and swelling after cataract surgery. its side effects may inclu
usage	labelled nepafenac (n390080). a non-steroidal anti-inflammatory with analgesic activity; selective cox-2 inhibitor. prodrug of amfenac